ADC Therapeutics SA (ADCT)vsInsmed Inc (INSM)
ADCT
ADC Therapeutics SA
$3.97
+0.76%
HEALTHCARE · Cap: $490.39M
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 645% more annual revenue ($606.42M vs $81.36M). ADCT leads profitability with a -1.8% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
ADCT
Avoid34
out of 100
Grade: F
INSM
Hold39
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 36.4% year-over-year
Conservative balance sheet, low leverage
No standout strengths identified
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -7.1% — below average capital efficiency
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ADCT
The strongest argument for ADCT centers on Revenue Growth, Debt/Equity. Revenue growth of 36.4% demonstrates continued momentum.
Bull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bear Case : ADCT
The primary concerns for ADCT are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Key Dynamics to Monitor
ADCT profiles as a hypergrowth stock while INSM is a turnaround play — different risk/reward profiles.
ADCT carries more volatility with a beta of 1.97 — expect wider price swings.
ADCT is growing revenue faster at 36.4% — sustainability is the question.
ADCT generates stronger free cash flow (-31M), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 34/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
ADC Therapeutics SA
HEALTHCARE · BIOTECHNOLOGY · USA
ADC Therapeutics SA, a biotechnology company focused on clinical stage oncology, develops Antibody Drug Conjugates (ADC) for patients suffering from hematologic malignancies and solid tumors. The company is headquartered in Epalinges, Switzerland.
Visit Website →Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?